Oncology NEWS International Vol 12 No 8

VEGF-Expressing TAMs Linked to Improved Colon Ca Survival

August 01, 2003

ROCHESTER, New York-Control of colon cancer may be mediated in part by the patient’s immune system, suggesting that treatments that enhance this innate capability could aid in reducing mortality. This is the principal conclusion taken from work carried out by Alok Khorana, MD, and his colleagues at the James P. Wilmot Cancer Center, University of Rochester Medical Center, and presented at the American Association for Cancer Research 94th Annual Meeting (abstract 512).

Capecitabine Shows Substantial Activity and Comparable Efficacy When Combined With Either Irinotecan or Oxaliplatin

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

PCTC Study Ended Early on Finding Proscar Significantly Reduces Prostate Cancer Risk

August 01, 2003

WASHINGTON- Researchers have closed the Prostate Cancer Prevention Trial (PCPT) 15 months early after finding that men who took Proscar (finasteride) had a 25% lower risk of developing the disease, compared with men given placebo. "This trial proves that prostate cancer, at least in part, is preventable. It is a huge step forward for cancer research," Peter Greenwald, MD, DrPH, director of the National Cancer Institute’s Division of Cancer Prevention, said at a press conference announcing the results.

Trials Support Efficacy of Imatinib Mesylate for GIST Patients But Disagree on Optimal Dose

August 01, 2003

CHICAGO-According to two parallel phase III clinical trials in the United States, Europe, and Asia, imatinib mesylate (Gleevec) is highly active in the treatment of gastrointestinal stromal tumors (GISTs). The optimal dose of the drug nevertheless is still unclear. While the safety profile was more favorable with a 400 mg/d dose than an 800 mg/d dose in both studies, the efficacy of the two doses diverged. In the US trial, progression-free survival was similar among patients who received 400 mg or 800 mg of imatinib. In the European trial, the 800-mg dose produced significantly improved progression-free survival.

Bexxar Approved for Relapsed/Refractory NHL

August 01, 2003

ROCKVILLE, Maryland-Bex-xar (tositumomab and iodine I-131 tositumomab) has received FDA approval for the treatment of patients with CD20-positive follicular non-Hodgkin’s lymphoma (NHL), with and without transformation, whose disease is refractory to rituximab (Rituxan) and has relapsed following chemotherapy. Bexxar will be co-marketed in the United States by Corixa Corporation, Seattle, and GlaxoSmith-Kline, Philadelphia.

Neoadjuvant Docetaxel Followed by Surgery, Doxorubicin/Cyclophosphamide, Radiation Is Active in Stage III Breast Ca

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

XELOX Prior to Chemoradiation and Total Mesorectal Excision Produces Almost Universal Tumor Regression

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Capecitabine in Combination With Weekly Docetaxel Appears to Produce Higher Response Rates Than Docetaxel Alone

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Gemcitabine/Capecitabine Combination Shows Modest Activity in Patients With Metastatic Renal Cell Carcinoma

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Options Explored for Treating Patients With Recurrent Colorectal Cancer Following IFL Therapy

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Chemoradiation With Capecitabine Appears To Be Well-Tolerated and May Replace Infusional 5-FU in Locally Advanced Rectal Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Capecitabine/Taxane Sequential Therapy May Benefit Social Functioning More Than Capecitabine/Taxane Simultaneous Therapy

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Phase II Study Makes Progress Toward an All-Oral Regimen for Advanced Breast Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Multicenter Phase II Data Support Effectiveness of Capecitabine/Irinotecan in Metastatic Colorectal Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Recently Released Data Show Benefits of FOLFOX4 Extend to Adjuvant Setting

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

European Study Finds Capecitabine/ Oxaliplatin May Be Suitable Option for Elderly Patients With Advanced Colorectal Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Capecitabine Research Continues to Shed Light on New Combinations of Agents to Treat Breast and Other Solid Tumors

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Overview of Studies Attests to Value of Capecitabine/Oxaliplatin Combination in Colorectal Cancer and Liver Metastases

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Multinational Trial Supports Use of Capecitabine Plus Oxaliplatin for Metastatic Colorectal Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Capecitabine/Oxaliplatin Combination Reduces Treatment Costs in Metastatic Colorectal Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Bevacizumab/IFL Prolongs Survival in Metastatic Colorectal Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Capecitabine Has Unique Qualities That May Make It A Suitable Substitute for 5-FU

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Gemcitabine Plus Paclitaxel Bests Paclitaxel Alone for Anthracycline- Pretreated Metastatic Breast Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Response to Fixed-Dose Capecitabine in Advanced Colorectal Cancer Is Comparable to Body Surface Area Calculated Dosing

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Every-3-Week Schedule of Irinotecan Plus Capecitabine Achieves Better Results Than Weekly Dosing as First-Line Therapy

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Improved Safety Profile of Capecitabine as Adjuvant Therapy Mirrors Metastatic Setting

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

‘FOLFOX Should Be Considered as First-Line Standard of Care Over IFL or IROX’

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Study Explores Whether Erlotinib Produces Additive Efficacy When Used With Capecitabine and Docetaxel

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Asian Study Suggests Combination of Docetaxel/Capecitabine Active in Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Lower Dose Capecitabine Is Active and Has Favorable Safety Profile in Elderly Patients With Advanced Breast Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

High Clinical Response Rate Achieved With Capecitabine/Radiotherapy in Locally Advanced Rectal Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Bevacizumab/IFL Shows ‘Substantial Activity’ in Advanced Colorectal Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.

Capecitabine/Irinotecan Active and Well-Tolerated as First-Line Therapy for Metastatic Colorectal Cancer

August 01, 2003

This special supplement to Oncology News International includes 28 reportswith updated information on clinical trials investigating capecitabine and other agents inthe treatment of advanced colorectal and breast cancers, and other solid tumors.The reports summarize selected presentations from the 39th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) and related educational symposiaheld in conjunction with ASCO.